风险投资公司a16z(Andreessen Horowitz)发布《长寿现状》分析报告,指出新冠疫情与生成式人工智能技术的普及正加速消费者从被动接受医疗服务转向主动管理个人健康 1。该报告基于对500名美国消费者的调查数据,探讨了建立统一医疗健康平台、无毒消费、多肽药物普及、胆固醇早期干预、新一代可穿戴设备及非侵入式脑机接口六大趋势 1。文章认为,能够连接测试数据与个性化治疗行动层的技术和产品将是未来巨大的商业机会,核心价值将从提供信息转移到帮助用户采取行动(如安排检查、预约、随访) 1。
在消费观念方面,调查显示63%的美国消费者知晓微塑料在体内的积累,62%愿意为标有“无毒”的产品支付更多费用 1。药物研发领域呈现新动向,GLP-1类药物(如司美格鲁肽)的成功激发了公众对未受监管的多肽(如BPC-157)的兴趣;礼来的替尔泊肽(tirzepatide)在2026年前九个月销售额近440亿美元 1。针对心血管健康,FDA于2026年7月批准了首款每日口服PCSK9抑制剂Lipfendra;但诺华公司针对脂蛋白(a)的药物pelacarsen试验虽降低指标但未达到主要心血管终点 1。此外,54%的受访者使用可穿戴设备,其中83%每天查看;FDA于2026年1月更新了一般健康政策,放宽了非侵入式穿戴设备的监管限制 1。在神经科技领域,Neuralink及加州大学旧金山分校(UCSF)团队在脑机接口领域取得进展,包括解码瘫痪患者言语;39%的消费者表示会使用非侵入式脑感应设备改善睡眠或专注力 1。
Andreessen Horowitz (a16z) has released a report titled "The State of Longevity," analyzing the rise of the "healthmaxxing" economy and its shift from passive medical treatment to proactive health management 1. The firm attributes this change in consumer behavior primarily to two accelerators: the global pandemic and the emergence of generative AI tools like ChatGPT, which have empowered individuals to take charge of their own well-being 1. According to the report, significant future business opportunities lie in technologies that do not merely provide information but create an "action layer," helping users schedule tests, make appointments, and follow through on personalized treatments 1.
Consumer Awareness and Toxicity Concerns
The study, based on survey data from 500 American consumers, highlights a growing awareness of environmental health risks 1. Specifically, 63% of respondents are aware of microplastic accumulation in their bodies, and 62% expressed a willingness to pay more for products labeled as "non-toxic" 1. This trend underscores a broader market movement toward wellness-focused consumption 1.
Pharmacological Advances and Lipid Management
In the pharmaceutical sector, the success of GLP-1 drugs, such as semaglutide, has sparked interest in unregulated peptides like BPC-157 1. Notably, Eli Lilly’s tirzepatide generated nearly $44 billion in sales during the first nine months of 2026 1. Concurrently, regulatory milestones have been achieved in cholesterol management; in July 2026, the FDA approved Lipfendra, the first daily oral PCSK9 inhibitor 1. However, challenges remain in other areas of cardiovascular health, as trials for lipoprotein(a)-targeting drugs, including Novartis’s pelacarsen, successfully lowered biomarkers but failed to meet primary cardiovascular endpoints 1.
Wearables and Brain-Computer Interfaces
The integration of technology into daily health monitoring is accelerating, with 54% of surveyed individuals using wearable devices, and 83% of those users checking their data daily 1. Regulatory environments have adapted to this growth, with the FDA updating its general health policy in January 2026 to relax restrictions on non-invasive wearable devices 1. Beyond standard wearables, advancements in brain-computer interfaces (BCIs) are gaining traction, exemplified by progress from Neuralink and the University of California, San Francisco (UCSF), particularly in decoding speech for paralyzed patients 1. Consumer appetite for this technology is evident, with 39% of respondents indicating they would use non-invasive brain-sensing devices to improve sleep or focus 1.
评论
还没有评论,欢迎留下第一条。